{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:56:55Z","timestamp":1793051815635,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multidrug-resistant tuberculosis (particularly resistant to pyrazinoic acid) is a life-threatening chronic pulmonary disease. Running a marketed regime specifically targets the ribosomal protein subunit-1 (RpsA) and stops trans-translation in the non-mutant bacterium, responsible for the lysis of bacterial cells. However, in the strains of mutant bacteria, this regime has failed in curing TB and killing pathogens, which may only because of the ala438 deletion, which inhibit the binding of pyrazinoic acid to the RpsA active site. Therefore, such cases of tuberculosis need an immediate and effective regime.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study has tried to determine and design such chemotypes that are able to bind to the mutant RpsA protein.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For these purposes, two phytochemical databases, i.e., NPASS and SANCDB, were virtually screened by a pharmacophore model using an online virtual screening server Pharmit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The model of pharmacophore was developed using the potential inhibitor (zr115) for the mutant of RpsA. Pharmacophore-based virtual screening results into 154 hits from the NPASS database, and 22 hits from the SANCDB database. All the predicted hits were docked in the binding pocket of the mutant RpsA protein. Top-ranked five and two compounds were selected from the NPASS and SANCDB databases respectively. On the basis of binding energies and binding affinities of the compounds, three compounds were selected from the NPASS database and one from the SANCDB database. All compounds were found to be non-toxic and highly active against the mutant pathogen. To further validate the docking results and check the stability of hits, molecular dynamic simulation of three compounds were performed. The MD simulation results showed that all these finally selected compounds have stronger binding interactions, lesser deviation or fluctuations, with greater compactness compared to the reference compound.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings indicate that these compounds could be effective inhibitors for mutant RpsA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13065-024-01182-7","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:01:36Z","timestamp":1713459696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["In silico identification of phytochemical inhibitors for multidrug-resistant tuberculosis based on novel pharmacophore generation and molecular dynamics simulation studies"],"prefix":"10.1186","volume":"18","author":[{"given":"Bader S.","family":"Alotaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","volume":"113","author":"J Chakaya","year":"2021","unstructured":"Chakaya J, Khan M, Ntoumi F, Aklillu E, Razia F, Mwaba P, Kapata N, Mfinanga S, Hasnain SE, Katoto PD. Global tuberculosis Report 2020\u2009\u2013\u2009reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113:S7\u201312.","journal-title":"Int J Infect Dis"},{"key":"1182_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2018.03.002","volume":"68","author":"S Tiberi","year":"2018","unstructured":"Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, et al. Taking forward the stop TB partnership and world health organization joint theme for world TB day march 24th 2018wanted: leaders for a TB-free world. You can make history. End TB Int J Infect Dis. 2018;68:122\u20134.","journal-title":"End TB Int J Infect Dis"},{"key":"1182_CR3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1590\/S1806-37132009001000011","volume":"35","author":"MB Conde","year":"2009","unstructured":"Conde MB, Melo FAFD, Marques AMC, Cardoso NC, Pinheiro VGF, Dalcin PDTR, Machado Junior A, Lemos ACM, Netto AR, Durovni B, et al. III Brazilian thoracic association guidelines on tuberculosis. J Bras Pneumol. 2009;35:1018\u201348.","journal-title":"J Bras Pneumol"},{"key":"1182_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fcimb.2018.00114","volume":"8","author":"HA Hameed","year":"2018","unstructured":"Hameed HA, et al. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. Front Cell Infect Microbiol. 2018;8:114.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"1182_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1128\/AAC.04541-14","volume":"59","author":"Q Xia","year":"2015","unstructured":"Xia Q, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59(3):1690\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1182_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.drudis.2016.09.010","volume":"22","author":"V Singh","year":"2017","unstructured":"Singh V, Mizrahi V. Identification and validation of novel drug targets in Mycobacterium tuberculosis. Drug Discovery Today. 2017;22:503\u20139.","journal-title":"Drug Discovery Today"},{"key":"1182_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","volume":"333","author":"W Shi","year":"2011","unstructured":"Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y. Pyrazinamide inhibits transtranslation in Mycobacterium tuberculosis. Science. 2011;333:1630\u20132.","journal-title":"Science"},{"key":"1182_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/fmb.14.125","volume":"10","author":"ES Zuniga","year":"2015","unstructured":"Zuniga ES, Early J, Parish T. The future for early-stage tuberculosis drug discovery. Future Microbiol. 2015;10:217\u201329.","journal-title":"Future Microbiol"},{"key":"1182_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/joim.12256","volume":"277","author":"A Zumla","year":"2015","unstructured":"Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson-Robertsson R, Doherty M, Andersson J, Maeurer M. Inflammation and tuberculosis: host-directed therapies. J Intern Med. 2015;277:373\u201387.","journal-title":"J Intern Med"},{"issue":"5","key":"1182_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/mmi.12892","volume":"95","author":"J Yang","year":"2015","unstructured":"Yang J, et al. Structural basis for targeting the ribosomal protein S 1 of M ycobacterium tuberculosis by pyrazinamide. Mol Microbiol. 2015;95(5):791\u2013803.","journal-title":"Mol Microbiol"},{"issue":"16","key":"1182_CR11","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1093\/nar\/gkp547","volume":"37","author":"P Salah","year":"2009","unstructured":"Salah P, et al. Probing the relationship between Gram-negative and Gram-positive S1 proteins by sequence analysis. Nucleic Acids Res. 2009;37(16):5578\u201388.","journal-title":"Nucleic Acids Res"},{"key":"1182_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bioorg.2018.09.024","volume":"82","author":"Y Zhi","year":"2019","unstructured":"Zhi Y, Dai Y, Yang J, Tan S, Lin D, Lin K. Lead compounds and key residues of ribosomal protein S1 in drug-resistant Mycobacterium tuberculosis. Bioorg Chem. 2019;82:58\u201367.","journal-title":"Bioorg Chem"},{"issue":"1","key":"1182_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/acsomega.1c04764","volume":"7","author":"A Wadood","year":"2021","unstructured":"Wadood A, Shareef A, Ur Rehman A, Muhammad S, Khurshid B, Khan RS, Afridi SG. In silico drug designing for ala438 deleted ribosomal protein S1 (RpsA) on the basis of the active compound zrl 15. ACS Omega. 2021;7(1):397\u2013408.","journal-title":"ACS Omega"},{"issue":"W1","key":"1182_CR14","doi-asserted-by":"publisher","first-page":"W442","DOI":"10.1093\/nar\/gkw287","volume":"44","author":"J Sunseri","year":"2016","unstructured":"Sunseri J, Koes DR. Pharmit: interactive exploration of chemical space. Nucleic Acids Res. 2016;44(W1):W442\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1182_CR15","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1021\/acs.jcim.8b00956","volume":"59","author":"AU Rehman","year":"2019","unstructured":"Rehman AU, et al. Exploring the pyrazinamide drug resistance mechanism of clinical mutants T370P and W403G in ribosomal protein S1 of Mycobacterium tuberculosis. J Chem Inf Model. 2019;59(4):1584\u201397.","journal-title":"J Chem Inf Model"},{"key":"1182_CR16","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1021\/jm9006966","volume":"52","author":"JJ Irwin","year":"2009","unstructured":"Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, Cao Y. Automated docking screens: a feasibility study. J Med Chem. 2009;52:5712\u201320.","journal-title":"J Med Chem"},{"key":"1182_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1758-2946-6-28","volume":"6","author":"X Wang","year":"2014","unstructured":"Wang X, Chen H, Yang F, Gong J, Li S, Pei J, Liu X, Jiang H, Lai L, Li H. iDrug: a web-accessible and interactive drug discovery and design platform. J Cheminformatics. 2014;6:28.","journal-title":"J Cheminformatics"},{"key":"1182_CR18","first-page":"5","volume":"9","author":"H Li","year":"2014","unstructured":"Li 18, Leung H, Ballester K-S,P.J. and, Wong M-H. Istar: a web platform for large-scale protein-ligand docking. PLoS ONE. 2014;9:5. e85678.","journal-title":"PLoS ONE"},{"key":"1182_CR19","doi-asserted-by":"publisher","first-page":"W615","DOI":"10.1093\/nar\/gkq322","volume":"38","author":"D Douguet","year":"2010","unstructured":"Douguet D. e-LEA3D: a computational-aided drug design web server. Nucleic Acids Res. 2010;38:W615\u201321.","journal-title":"Nucleic Acids Res"},{"key":"1182_CR20","doi-asserted-by":"publisher","first-page":"W448","DOI":"10.1093\/nar\/gkv306","volume":"43","author":"CM Labb\u00b4e","year":"2015","unstructured":"Labb\u00b4e CM, Rey J, Lagorce D, Vavru\u02c7sa M, Becot J, Sperandio O, Villoutreix BO, Tuff\u00b4ery P, Miteva MA. MTiOpenScreen: a web server for structure-based virtual screening. Nucleic Acids Res. 2015;43:W448\u201354.","journal-title":"Nucleic Acids Res"},{"key":"1182_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, Case DA, Walker RC. An overview of the Amber biomolecular simulation package. Wiley Interdiscip Rev Comput Mol Sci. 2013;3:198\u2013210.","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"1182_CR22","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L. Particle mesh Ewald: An N\u00b7 log (N) method for Ewald sums in large systems. J Chem Phys. 1993;98:10089\u201392.","journal-title":"J Chem Phys"},{"key":"1182_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert J-P, Ciccotti G, Berendsen J. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23:327\u201341.","journal-title":"J Comput Phys"},{"key":"1182_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF01008729","volume":"9","author":"R Zwanzig","year":"1973","unstructured":"Zwanzig R. Nonlinear generalized Langevin equations. J Stat Phys. 1973;9:215\u201320.","journal-title":"J Stat Phys"},{"key":"1182_CR25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1021\/ct200909j","volume":"8","author":"AW G\u00f6tz","year":"2012","unstructured":"G\u00f6tz AW, Williamson MJ, Xu D, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born. J Chem Theory Comput. 2012;8:1542\u201355.","journal-title":"J Chem Theory Comput"},{"key":"1182_CR26","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/gcb.14619","volume":"25","author":"S Piao","year":"2019","unstructured":"Piao S, Liu Q, Chen A, Janssens IA, Fu Y, Dai J, Liu L, Lian X, Shen M, Zhu X. Plant phenology and global climate change: current progresses and challenges. Global Change Biol. 2019;25:1922\u201340.","journal-title":"Global Change Biol"},{"key":"1182_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321.","journal-title":"N Engl J Med"},{"key":"1182_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/prot.340170408","volume":"17","author":"A Amadei","year":"1993","unstructured":"Amadei A, Linssen AB, Berendsen HJ. Essential dynamics of proteins. Proteins. 1993;17:412\u201325.","journal-title":"Proteins"},{"issue":"18","key":"1182_CR29","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.1080\/07391102.2022.2138550","volume":"41","author":"A Ajmal","year":"2023","unstructured":"Ajmal A, Ali Y, Khan A, Wadood A, Rehman AU. Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling. J Biomol Struct Dynamics. 2023;41(18):8866\u201375.","journal-title":"J Biomol Struct Dynamics"},{"key":"1182_CR30","doi-asserted-by":"publisher","first-page":"p1159389","DOI":"10.3389\/fcimb.2023.1159389","volume":"13","author":"A Ajmal","year":"2023","unstructured":"Ajmal A, Mahmood A, Hayat C, Hakami MA, Alotaibi BS, Umair M, Abdalla AN, Li P, He P, Wadood A, Hu J. Computer-assisted drug repurposing for thymidylate kinase drug target in monkeypox virus. Front Cell Infect Microbiol. 2023;13:p1159389.","journal-title":"Front Cell Infect Microbiol"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01182-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-024-01182-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01182-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:04:08Z","timestamp":1713459848000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-024-01182-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1186\/s13065-024-01182-7","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have not performed work on human\/animal; therefore, there is no need of informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}